These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30248063)

  • 21. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly.
    Fernández-Ferreira R; García-Santos RA; Rodríguez-Violante M; López-Martínez C; Becerra-Laparra IK; Torres-Pérez ME
    Rev Esp Geriatr Gerontol; 2019; 54(5):251-256. PubMed ID: 31324404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Video-oculographic biomarkers for evaluating vertical ocular dysfunction in progressive supranuclear palsy.
    Quattrone A; Crasà M; Morelli M; Vescio B; Augimeri A; Gramigna V; Quattrone A
    Parkinsonism Relat Disord; 2022 Jun; 99():84-90. PubMed ID: 35642995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frontal deficits differentiate progressive supranuclear palsy from Parkinson's disease.
    Lee YE; Williams DR; Anderson JF
    J Neuropsychol; 2016 Mar; 10(1):1-14. PubMed ID: 25223526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.
    Quattrone A; Morelli M; Nigro S; Quattrone A; Vescio B; Arabia G; Nicoletti G; Nisticò R; Salsone M; Novellino F; Barbagallo G; Le Piane E; Pugliese P; Bosco D; Vaccaro MG; Chiriaco C; Sabatini U; Vescio V; Stanà C; Rocca F; Gullà D; Caracciolo M
    Parkinsonism Relat Disord; 2018 Sep; 54():3-8. PubMed ID: 30068492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders.
    Watanabe Y; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Uchiyama T; Kadowaki T; Matsubara T; Hirata K
    Intern Med; 2017 Nov; 56(21):2871-2878. PubMed ID: 28943542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy.
    Nigro S; Arabia G; Antonini A; Weis L; Marcante A; Tessitore A; Cirillo M; Tedeschi G; Zanigni S; Calandra-Buonaura G; Tonon C; Pezzoli G; Cilia R; Zappia M; Nicoletti A; Cicero CE; Tinazzi M; Tocco P; Cardobi N; Quattrone A
    Eur Radiol; 2017 Jun; 27(6):2665-2675. PubMed ID: 27761709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilizing speech analysis to differentiate progressive supranuclear palsy from Parkinson's disease.
    Kang K; Nunes AS; Sharma M; Hall AJ; Mishra RK; Casado J; Cole R; Derhammer M; Barchard G; Najafi B; Vaziri A; Wills AM; Pantelyat A
    Parkinsonism Relat Disord; 2023 Oct; 115():105835. PubMed ID: 37678101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computed tomographic findings of progressive supranuclear palsy compared with Parkinson's disease.
    Yuki N; Sato S; Yuasa T; Ito J; Miyatake T
    Jpn J Med; 1990; 29(5):506-11. PubMed ID: 2089174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
    Paviour DC; Thornton JS; Lees AJ; Jäger HR
    Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
    Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
    Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
    Litvan I; Mangone CA; McKee A; Verny M; Parsa A; Jellinger K; D'Olhaberriague L; Chaudhuri KR; Pearce RK
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow.
    Fukui Y; Hishikawa N; Sato K; Yunoki T; Kono S; Matsuzono K; Nakano Y; Ohta Y; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2015 Oct; 357(1-2):178-82. PubMed ID: 26227830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease.
    Somme J; Gómez-Esteban JC; Tijero B; Berganzo K; Lezcano E; Zarranz JJ
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1230-3. PubMed ID: 23253819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
    Shill HA; Zhang N; Driver-Dunckley E; Mehta S; Adler CH; Beach TG
    Mov Disord; 2021 Jul; 36(7):1700-1704. PubMed ID: 33755262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease.
    Pellicano C; Assogna F; Cellupica N; Piras F; Pierantozzi M; Stefani A; Cerroni R; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Parkinsonism Relat Disord; 2017 Dec; 45():50-56. PubMed ID: 29037499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.